Targocil

Research use only, not for human use.

Targocil is used as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) (MIC90s: 2 μg/ mL) for both MRSA and MSSA.

Targocil is used as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) (MIC90s: 2 μg/ mL) for both MRSA and MSSA.

MICs of Targocil against S. aureus strains Newman, MW2, MG2375, and MG2389 are 1 μg/mL for all strains. Targocil shows excellent activity against S. aureus isolates from suspected cases of bacterial keratitis, including both MSSA and MRSA isolates, with MICs that range from 1 to 2 μg/ mL. Targocil, a derivative of 1835F03, exhibits better activity against all keratitis isolates than the original lead compound, 1835F03. Bovine serum exhibits a detectable but moderate inhibitory effect on the in vitro antimicrobial activities of both 1835F03 and Targocil, increasing the MICs of both by 4- to 8-fold. Compare to the vehicle alone, Targocil at 5 μg/mL exhibits little toxicity for HCECs, even after 24 h of exposure. However, 40 μg/mL Targocil shows toxicity at all time points tested.

——

——

Endocrinology/Hormones

5-HT Receptor

Others

Infection

——

1200443-21-5

475.95

C21H22ClN5O4S

>98% (HPLC)

DMSO : 33.33 mg/mL. 70.03 mM; H2O : < 0.1 mg/mL

CCN(CC)c1nc2c(nnn2c2cc(c(cc12)OC)OC)S(=O)(=O)c1ccc(cc1)Cl

——

(-20℃)

With Ice Pack

≥ 2 years